Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome.

ABSTRACT:

Background

Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a monoclonal antibody against interleukin-5 receptor α, which is expressed on human eosinophils.

Methods

In this randomized, double-blind, placebo-controlled, phase 2 trial, we administered a series of three monthly subcutaneous injections of either benralizumab (at a dose of 30 mg) or placebo in 20 symptomatic patients who had PDGFRA-negative hypereosinophilic syndrome and an absolute eosinophil count of at least 1000 cells per cubic millimeter; all the patients were receiving stable therapy (drugs or dietary changes) for this disease. This regimen was followed by an open-label phase, during whi

SUBMITTER: Kuang FL 

PROVIDER: S-EPMC6557265 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature